ProQuad (measles, mumps, rubella and varicella virus vaccine live) / Merck (MSD) - LARVOL DELTA

Effects of Thermal and Antibiotic Treatments on the Viral Accumulation of FcMV1 in Fusarium circinatum Isolates. (PubMed, J Fungi (Basel)) - "For this purpose, three replicates of each isolate were exposed to thermal treatment (38 °C) and antibiotic treatment (ribavirin, cycloheximide, kanamycin, and rifampicin mixed with cAMP)(cyclic adenosine monophosphate) for five successive passages. The isolate Fc179 was found to be more prone to antibiotic treatment than the other two isolates (001 and Va221). This study demonstrated the possibility of using some isolates of F. circinatum for fine-tuning cures for mitovirus, in order to create virus-free strains for biological control in the future."

Journal • Infectious Disease

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age (clinicaltrials.gov) - P2 | N=801 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Measles • Mumps • Rubella • Varicella Zoster

Cystine-knot peptide inhibitors of HTRA1 bind to a cryptic pocket within the active site region. (PubMed, Nat Commun) - "The opening and closing of this cryptic pocket is controlled by the gatekeeper residue V221, and its movement is facilitated by the absence of a constraining disulfide bond that is typically present in trypsin fold serine proteases, thereby explaining the remarkable selectivity of the CKPs. Our findings reveal an intriguing mechanism for modulating the activity of HTRA1, and highlight the utility of CKP-based phage display platforms in uncovering potent and selective inhibitors against challenging therapeutic targets."

Journal • Age-related Macular Degeneration • Immunology • Macular Degeneration • Ophthalmology • Osteoarthritis • Pain • Retinal Disorders • Rheumatology • HTRA1

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age (clinicaltrials.gov) - P2 | N=801 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2024 ➔ Oct 2024 | Trial primary completion date: Jan 2024 ➔ Jun 2024

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Measles • Mumps • Rubella • Varicella Zoster